Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Trading of Depomed Common Stock Halted
Advisory Committee of the Food and Drug Administration to Discuss SEFELSA™ New Drug Application for the Treatment of Moderate to Severe Vasomotor Symptoms Conference Call Later Today NEWARK, Calif. , March 4, 2013 /PRNewswire/ --  Depomed, Inc. (NASDAQ:DEPO) announced that NASDAQ has halted trading
Toggle Summary THE MICHAEL J. FOX FOUNDATION AWARDS DEPOMED A SECOND DEVELOPMENT GRANT IN PARKINSON'S DISEASE
MENLO PARK, Calif. - October 11, 2010 - Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a clinical grant by The Michael J. Fox Foundation under its Clinical Intervention Awards 2010 program.  The modest grant amount supports Depomed in the development of a gastric retentive
Toggle Summary The Michael J. Fox Foundation Awards Depomed a Preclinical Development Grant for Levodopa/Carbidopa in Parkinson's Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--July 23, 2008--Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation's Therapeutics Development Initiative 2008 Program. The modest grant amount supports Depomed in the

Upcoming Events

There are currently no events to display.
Presentations

Recent SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Initial filing by director officer or owner of more than ten percent.

3
3,4,5
View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

An amendment to the SC 13G filing

SC 13G/A
3,4,5
View HTML

Annual filing director officer or owner of more than ten percent.

5
3,4,5
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com